Comparison of different conditioning regimens in allogeneic hematopoietic stem cell transplantation shows superiority of total body irradiation based regimen for younger acute leukemia patients: a nationwide study

Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackground/AimThe optimal the conditioning regimens for allogeneic hematopoietic stem cell transplantation (HSCT), especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4,255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1,562 myeloablative conditioning (MAC) and 2,693 non-myeloablative conditioning (NMC) groups, the overall survival (OS) was not statistically different. However in MAC group, the OS of total body irradiation (TBI)-based regimen were superior than that of chemotherapy-alone regimen (p=0.005). In subgroup analysis, the superiority of TBI-based regimen was especially prominent in acute leukemia (p=0.012 for acute myeloid leukemia; p=0.005 for acute lymphoblastic leukemia) and younger patients (
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

Fenntartó kezelési módok felnőttkori rosszindulatú hematológiai betegségekben. Orv Hetil. 2020 Sep;161(38):1623-1628 Authors: Udvardy M Abstract Maintenance therapy has been the strong and standard element of many acute lymphoblastic leukaemia protocols, used much less frequently and systematically in adult oncohematological disorders. The first adult maintenance efforts appeared in follicular and mantle cell lymphoma (mostly monoclonal antibody based), along with an early maintenance effort to prolong the plateau phase of myeloma. For the time being, after a...
Source: Orvosi Hetilap - Category: General Medicine Authors: Tags: Orv Hetil Source Type: research
CONCLUSIONS: There was no convincing evidence of an increased risk in any hematological malignancy when interpreting the results from both series of analyses. PMID: 32818321 [PubMed - as supplied by publisher]
Source: Transfusion - Category: Hematology Authors: Tags: Transfusion Source Type: research
CD123 is overexpressed in many hematological malignancies and found to be useful in characterising leukemic blasts of both acute myeloid leukemia (AML) and B-acute lymphoblastic leukemia (B-ALL). CD123 has been recently found to be a marker of leukemic stem cells and its utility to measure residual disease and potential role in disease relapse is under evaluation. Herein, we have evaluated the expression of CD123 in 757 samples of acute leukaemia including 479 treatment na ïve and 278 follow-up samples and compared with post-induction morphological remission (CR) and measurable residual disease (MRD) status.
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
AbstractThe introduction of chimeric antigen receptor T cell (CAR T) therapy has resulted in a paradigm shift in the management of relapsed/refractory B cell malignancies. Patients with acute lymphoblastic leukemia and non ‐Hodgkin’s lymphoma who had exhausted all meaningful treatment options now have an opportunity for long‐term remission and possibly cure. CAR T is rapidly expanding into the treatment paradigm for multiple myeloma with approvals expected in the near future. CAR T for chronic lymphocytic leukem ia may not be far behind, while CAR T studies in Hodgkin lymphoma and acute myeloid leukemia are ongoi...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: SI ON STEM CELL TRANSPLANTATION Source Type: research
ConclusionsFLT3 mutation was not common in Chinese ALL patients. Age of onset, platelet counts and transplant status rather than FLT3 mutations were independent prognostic variables for ALL cases on OS in our cohort. In spite of small sample size, ETP-ALL may indicate a comparable higher FLT3-mutant rate. Since ETP-ALL has been identified as high-risk subgroup, these data warrant clinical studies with the implementation of FLT3 inhibitors in addition to early allogeneic hematopoietic stem cell transplantation for FLT3 mutant ETP-ALL.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
This study aimed to analyze the role of postoperative treatment for BC in the development of subsequent HM. Using the French National Health Data System, we examined the HM risks in patients diagnosed with an incident primary breast cancer between 2007 and 2015, who underwent surgery as first-line treatment for BC. Main outcomes were acute myeloid leukemia (AML), Myelodysplastic syndrome (MDS), myeloproliferative neoplasms (MPNs), multiple myeloma (MM), Hodgkin’s lymphoma or non-Hodgkin’s lymphoma (HL/NHL), and acute lymphoblastic leukemia or lymphocytic lymphoma (ALL/LL). Analyses were censored at HM o...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Publication date: Available online 26 August 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Hyunkyung Park, Ja Min Byun, Youngil Koh, Sung-Soo Yoon, Hyejoo Park, Jayoun Lee, Sang-Jin Shin, Jeonghwan YoukAbstractBackgroundThe optimal the conditioning regimens for allogeneic hematopoietic stem-cell transplantation, especially for East Asian patients, remains unknown.Patients and MethodsWe collected and analyzed clinical and survival data of 4255 patients from the Korean National Health Insurance Claims Database.ResultsBetween 1562 myeloablative conditioning and 2693 nonmyeloablative conditioning groups, the ove...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Auer rods were first described in the cytoplasm of leukemia blasts by John Auer in 1906. Auer rods are commonly seen in myeloid progenitors, and serve as a diagnostic morphological feature of acute myeloid leukemia (AML) [1]. The differential diagnosis of hematopoietic neoplasms relies on the detection of cytoplasmic inclusions resembling Auer rods. Auer rod-like inclusions have been described in multiple myeloma [2], prolymphocytic leukemia (PLL) [3], B-cell acute lymphoblastic leukemia [4], chronic lymphocytic leukemia [4], splenic lymphoma [5] and nodal marginal zone lymphoma [6], which are quite distinct from the needl...
Source: Experimental Hematology - Category: Hematology Authors: Tags: Brief Communication Source Type: research
Yi He†, Wenyong Long† and Qing Liu* Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, China Super-enhancers (SEs) refer to large clusters of enhancers that drive gene expressions. Recent data has provided novel insights in elucidating the roles of SEs in many diseases, including cancer. Many mechanisms involved in tumorigenesis and progression, ranging from internal gene mutation and rearrangement to external damage and inducement, have been demonstrated to be highly associated with SEs. Moreover, translocation, formation, deletion, or duplication of SEs themselves co...
Source: Frontiers in Pharmacology - Category: Drugs & Pharmacology Source Type: research
Conclusions: CAR T cell therapies have demonstrated the clinical benefits of harnessing our body's own defenses to combat tumor cells. Similar research is being conducted on lesser known modifications and gene-modified immune cells, which we highlight in this review. Introduction Chimeric antigen receptors and engineered T cell receptors (based on previously identified high affinity T cell receptors) function by redirecting T cells to a predefined tumor-specific (or tumor-associated) target. Most of these modifications use retroviral or lentiviral vectors to integrate the construct, and most of the receptors ...
Source: Frontiers in Oncology - Category: Cancer & Oncology Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Acute Myeloid Leukemia | Cancer & Oncology | Chemotherapy | Databases & Libraries | Health Insurance | Insurance | Leukemia | Lymphoma | Myeloma | Statistics | Stem Cell Therapy | Stem Cells | Study | Transplants